Compared with parental K562 cells, TXNIP was dramatically decreased in both K562G and K562R cells (Fig. 4G), indicating altered expression of TXNIP is an early event during the resistance of CML to imatinib. The gene discussed is TXNIP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.